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Gastroenterology and Hepatology, St Antonius Hospital Nieuwegein, Nieuwegein, The NetherlandsBACKGROUND & AIMS: Surveillance is recommended for patients with long-term inflammatory bowel disease because
they have an increased risk of colorectal cancer (CRC). To study the effectiveness of surveil-
lance, we determined the incidence of CRC after negative findings from surveillance colonos-
copies (interval CRC).METHODS: We collected data from 1273 patients with ulcerative colitis or Crohn’s disease, enrolled in a sur-
veillanceprogramat7hospitals inTheNetherlands,whounderwent4327surveillancecolonoscopies
fromJanuary1,2000, through January1,2014.Patientswere followedup fromtheirfirst surveillance
colonoscopy until the last surveillance colonoscopy, colectomy, or CRC. Factors that might have
contributed to the occurrence of CRC were categorized as inadequate procedures (ie, inadequate
bowel preparation), inadequate surveillance (CRC occurring outside the appropriate surveillance
interval), or inadequate management of dysplasia (CRC diagnosed in the same colonic segment as a
previous diagnosis of dysplasia). The remaining CRC cases were classified as true interval CRCs.RESULTS: CRC was diagnosed in 17 patients (1.3%), with an incidence of 2.5 per 1000 years of follow-up
evaluation. Factors that might account for the occurrence of CRC were identified in 12 patients
(70%). These were inadequate colonoscopies in 4 patients (24%), inadequate surveillance
intervals in 9 patients (53%), and inadequate management of dysplasia in 2 patients (12%).
The remaining 5 cases of CRC (30%) were classified as true interval CRCs.CONCLUSIONS: In a retrospective analysis of patients with inflammatory bowel disease participating in a
surveillance program, the incidence of CRC was only 1%, which supports the implementation of
longer surveillance intervals. However, the fact that 30% of CRC cases were interval cancers
indicates the need for variable surveillance intervals based on risk factors for CRC.Keywords: Inflammatory Bowel Disease; Surveillance; Interval Colorectal Cancer.Abbreviations used in this paper: AGA, American Gastroenterological As-
sociation; BSG, British Society of Gastroenterology; CD, Crohn’s disease;
CRC, colorectal cancer; DTC, diagnosis treatment combinations; HGD,
high-grade dysplasia; IBD, inflammatory bowel disease; LGD, low-grade
dysplasia; PSC, primary sclerosing cholangitis; UC, ulcerative colitis.
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http://dx.doi.org/10.1016/j.cgh.2015.04.183Both ulcerative colitis (UC) and Crohn’s colitis (CD)are associated with an increased risk of devel-
oping colorectal cancer (CRC).1,2 Therefore, regular
endoscopic surveillance is recommended, which aims to
achieve a reduction in CRC-related deaths by detecting
and treating premalignant lesions (dysplasia) and early
stage asymptomatic CRC.3,4 There has been much debate
regarding whether this strategy is (cost) effective, mainly
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veillance is limited.5,6
The lack of solid evidence for CRC surveillance in
IBD patients also is reflected by the differences in the
recommended surveillance intervals of the recently
updated British Society of Gastroenterology (BSG) and
American Gastroenterological Association (AGA) sur-
veillance guidelines.3,4 The BSG guideline adopted a
risk-stratified approach based on known risk factors for
IBD-associated CRC with corresponding surveillance in-
tervals of 1, 3, and 5 years, whereas the authors of the
AGA guidelines stated that optimal surveillance intervals
cannot be defined clearly and therefore recommend that
surveillance should be performed every 1 to 3 years.
Determining the optimal surveillance interval is impor-
tant because a shorter interval leads to unnecessary high
costs and burdens the patient, whereas a longer interval
could decrease the effectiveness of surveillance and may
result in an increased incidence of CRC detected between
2 surveillance colonoscopies (interval CRC).
Because a direct prospective comparison between
different surveillance intervals probably never will be
performed, data on the occurrence of interval CRCs
among IBD patients undergoing regular surveillance
could provide vital information on whether current sur-
veillance protocols are effective.7 The occurrence of in-
terval CRCs among IBD patients undergoing surveillance
largely is unknown, although 1 study reported that as
many as 50% of the CRCs diagnosed during the surveil-
lance program were interval CRCs.8 These data date back
to the 1970s, however, and it is not clear if these results
can be extrapolated to the present clinical situation.
The aim of the current study therefore was to
establish the incidence of interval CRCs in a cohort of IBD
patients undergoing regular colonoscopic surveillance.
Furthermore, we aimed to identify procedure-related
factors potentially explaining the occurrence of CRC.Methods
Patients
All patients with a diagnosis of CD or UC from 5
university hospitals and 2 general hospitals were iden-
tified using the diagnosis treatment combinations (DTCs)
for IBD. DTCs are based on the International Classifica-
tion of Diseases codes and can be considered the Dutch
version of the Diagnosis Related Groups, as used in other
countries (eg, the United States).
The medical records and endoscopy reports of all
patients with a DTC code for CD or UC were reviewed to
confirm the IBD diagnosis and to assess whether patients
had a valid indication for surveillance colonoscopy ac-
cording to the new AGA and BSG guidelines. Because the
new BSG and AGA guidelines do not concur with regard
to the beginning of surveillance (10 and 8 years after the
onset of colitis symptoms, respectively), we consideredpatients with a disease duration of at least 8 years to be
eligible for surveillance. Patients with colitis and a
concomitant diagnosis of primary sclerosing cholan-
gitis (PSC) were considered to have an indication for
surveillance immediately after diagnosis whereas pa-
tients with proctitis or proctosigmoiditis (UC patients) or
with involvement of less than 30% of the colonic mucosa
(CD patients) were considered to have no indication for
surveillance and were excluded.
Furthermore, patients with any previous diagnosis of
neoplasia (other than discrete solitary sessile or pedun-
culated polyps suggestive of sporadic adenomas and
containing adenomatous tissue on histology) or (sub)
total colectomy before the first surveillance colonoscopy
were excluded.
Demographic and clinical data were collected from
the medical records and included date of IBD diagnosis,
type of IBD, disease extent before the start of surveil-
lance, family history of CRC, medication use, and a
concomitant diagnosis of PSC. In UC and IBD-unclassified
patients, disease extent was defined as either left-sided
or extensive (inflammation distal or proximal to the
splenic flexure, respectively). In patients with CD, in-
volvement of 3 or more anatomic parts of the colon was
considered extensive disease, whereas involvement of 1
or 2 sections was considered limited disease.
Patients were followed up from the date of the first
surveillance colonoscopy after January 1, 2000, until the
last surveillance colonoscopy before January 7, 2014,
(sub)total colectomy, or the diagnosis of CRC.
Surveillance Colonoscopies
During the study period all participating centers
performed surveillance in accordance with international
guidelines (ie, complete colonic inspection with or
without the use of chromoendoscopy and biopsy sam-
pling of all areas suspicious for neoplasia, as well as
sampling of 4 random biopsy specimens every 10 cm
when chromoendoscopy was not performed).
All endoscopy reports were reviewed to confirm that
patients underwent at least 2 surveillance colonoscopies.
A surveillance colonoscopy was defined as a procedure
with the clear intention to detect neoplasia (explicitly
stated as the indication for the colonoscopy and/or by
the use of chromoendoscopy or taking 4-quadrant
random biopsy specimens every 10 cm).
Potential quality indicators such as cecal intubation
and the number of random biopsy specimens were
collected from the endoscopy reports. Insufficient bowel
preparation was recorded if this was stated as such in
the endoscopy report. Furthermore, known endoscopic
risk factors for IBD-associated CRC were collected such
as the extent and severity of inflammation and the pre-
sence of post-inflammatory polyps or strictures.
For all lesions that were detected during the follow-up
period and suspected of containing dysplasia, the location,
endoscopic description, and treatment were recorded.




Male sex 676 (53)
IBD diagnosis
Ulcerative colitis 804 (63)
Distal splenic flexure 269 (33)
Proximal splenic flexure 456 (57)
Unknown 79 (10)
Crohn’s colitis 434 (34)
Segmental colitis, <50% 159 (37)
Segmental colitis, >50% 228 (52)
Unknown 47 (11)
Indeterminate colitis 35 (3)
Segmental colitis, <50% 16 (46)
Segmental colitis, >50% 18 (51)
Unknown 1 (3)
Age at first surveillance colonoscopy, mean (SD), y 45.8 (12.9)
Duration of IBD at first surveillance colonoscopy,
mean (SD), y
17.4 (3.9)
Concomitant diagnosis of PSC 173 (14)
Duration of follow-up evaluation, mean (SD), y 5.3 (3.0)
Table 2. Endoscopic Characteristics
N (%)
Total number of surveillance colonoscopies 4327 (100)
WLE þ random biopsies 3887 (90)
Chromoendoscopy 440 (10)
Surveillance colonoscopies, median (range) 2 (1–11)
Cecal intubation 4288 (99)
Suboptimal bowel preparation 566 (13)
Biopsy specimens per colonoscopy, mean (SD) 27 (12)
Endoscopic inflammation
No active inflammation 2847
Mild 1182
Moderate to severe 298
Histologic inflammation
No active inflammation 2383
Mild 1429
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nondysplastic, indefinite for dysplasia, low-grade dysplasia
(LGD), high-grade dysplasia (HGD), or colorectal cancer
(CRC). Endoscopically visible lesions containing LGD were
subdivided into adenoma-like masses (discrete solitary
sessile or pedunculated polyps resembling sporadic ade-
nomas and containing adenomatous tissue on histology)
and non–adenoma-like masses (all other endoscopic de-
scriptions; ie, plaque-like lesions, irregular masses).
Colorectal Cancer Characteristics
Each diagnosis of CRC within the surveillance program
was categorized according to its most probable explana-
tion, adopted from similar studies on sporadic CRC.9
Procedure-related CRCs were defined as inadequate
bowel preparation, incomplete intubation, or fewer than
10 random biopsy specimens sampled during the sur-
veillance colonoscopy before the CRC diagnosis. Inade-
quate surveillance was defined as CRC occurring outside
the appropriate surveillance interval. Because the 2002
BSG guidelines were followed during the study period, we
considered a 1-year surveillance interval appropriate for
patientswith prior dysplasia or a concomitant diagnosis of
PSC and a 2-year surveillance interval for the remaining
patients. We also stratified patients in the 1-year, 3-year,
and 5-year surveillance intervals based on the risk factors
described in the newBSG guidelines. Inadequate dysplasia
management was defined as CRC diagnosed in the same
colonic segment as a previous diagnosis of dysplasia.
Definition of Interval Colorectal Cancer
All cases of CRC detected within the appropriate sur-
veillance interval, after an adequately performed sur-
veillance colonoscopy, were considered interval cancers.
In other words, these were cases of CRC that could be
explained only by either missed lesions during the pre-
ceding colonoscopy or rapid progression to cancer within
the surveillance interval. In a second analysis we defined
interval CRCs as advanced stage CRC (Dukes stages C or D)
diagnosed within the appropriate surveillance interval, in
accordance with the definition used by Rutter et al.8
Results
Surveillance Cohort
A total of 1273 IBD patients were identified who were
enrolled in a surveillance program, of whom 434 patients
had CD (34%), 804 had UC (63%), and 35 had IBD un-
classified (3%). Baseline characteristics are shown in
Table 1.
During a mean follow-up period of 5.3 years (3.0 y),
4327 surveillance colonoscopies were performed in the
study population, comprising 6823 years of follow-up
evaluation. Surveillance was performed with randombiopsy sampling in 3887 procedures (90%), during
which a mean of 27 biopsy specimens (12) were
sampled (Table 2). The remaining 440 surveillance
procedures (10%) were performed using chromoendo-
scopy with targeted biopsies. The cecal intubation rate
was 99%, and bowel preparation was deemed adequate
in 87% of procedures.Incidence of Dysplasia During Follow-Up
Evaluation
LGD was detected during 354 surveillance colonos-
copies in 265 patients (21%) during the follow-up
September 2015 Interval CRC Among IBD Patients 1659evaluation, comprising 482 lesions with LGD. These le-
sions were classified as 339 adenomas, 43 non–adenoma-
like lesions, and 100 episodes of flat dysplasia, originating
from a total of 107,969 random biopsy specimens. The
incidence of LGD was 52 per 1000 years of follow-up
evaluation.
HGD was detected during 19 surveillance colonos-
copies in 19 patients (1.5%), with an incidence of 2.8 per
1000 years of follow-up evaluation. HGD was found in a
random biopsy specimen in 2 patients (0.2%), and in a
lesion in the remaining 17 patients (1.3%).Incidence of Colorectal Cancer During
Follow-Up Evaluation
In total, 18 CRCs were diagnosed in 17 patients (1.3%)
at a median age of 55 years with an incidence rate of 2.5
per 1000 years of follow-up evaluation (Table 3). CRC
was detected during a scheduled surveillance colonos-
copy in 14 patients. The remaining 3 CRCs were detected
during colonoscopy for an indication other than surveil-
lance, as an incidental finding during ileocecal resection,
or after analysis of liver metastases with an unknown
primary tumor.
A schematic presentation of all surveillance colonos-
copies and diagnoses of dysplasia before the CRC diag-
nosis for each individual patient are shown in Figure 1.
The median interval between the last surveillance colo-
noscopy and the CRC diagnosis was 22 months (range,
9–42 mo).Factors Potentially Explaining the Occurrence
of Colorectal Cancer
An inadequate colonoscopy was identified as the
most likely cause in 4 patients (24%) (Figure 2). An
inadequate surveillance interval was identified as an
etiologic factor in 9 patients (53%) according to the
previous BSG and AGA guidelines, and in 6 patients
(35%) when patients were stratified according to the
surveillance intervals of the updated BSG guideline.Table 3. Neoplasia During Follow-Up Evaluation, Based on
the Maximal Grade of Dysplasia
N (%)
Surveillance colonoscopies 4327 (100)
Colonoscopies with neoplasia 438 (10)
Colonoscopies with IFD 69 (2)
Lesions containing LGD 482 (11)
Adenoma-like mass 339 (70)
Flat dysplasia 100 (21)
Non–adenoma-like mass 43 (9)
HGD 19 (0.4)
CRC 17 (0.4)
IFD, indefinite for dysplasia.Two patients (12%) had either flat LGD originating
from random biopsy specimens (n ¼ 1) or LGD in an
endoscopically resected lesion (n ¼ 1) during the sur-
veillance procedure directly before the CRC diagnosis,
which was located in the same colonic segment as the
CRC (inadequate dysplasia management).
Five cases of CRC (30%) could be classified as inter-
val CRC according to our definition of CRC diagnosed
within the appropriate surveillance interval after an
adequately performed surveillance colonoscopy, result-
ing in an incidence of 0.2 interval CRCs per 1000 years of
follow-up evaluation. Interestingly, all 5 cases were
advanced stage CRC, Dukes C or D, and therefore could
be classified as interval cancers according to our second
definition for interval CRC as well. Because the remaining
3 cases of CRC diagnosed at an advanced stage all were
diagnosed outside the appropriate surveillance interval,
the rate of interval CRC was equal for both definitions.
Three cases of interval CRC were identified during a
regular surveillance colonoscopy at the appropriate in-
terval, 1 during a colonoscopy for abdominal pain and 1
for liver metastases with an unknown primary tumor.
Three interval CRCs (60%) were located in the right
colon, as compared with 8 of the remaining 12 CRCs
(67%). Three patients with interval CRC had UC (60%),
none had a concomitant diagnosis of PSC, and 2 patients
had postinflammatory polyps (40%).Discussion
This study shows that the incidence of CRC among
IBD patients enrolled in a surveillance program is low
compared with previous studies, with only 17 cancers
detected during 6823 years of follow-up evaluation.8
The majority of CRC cases (70%) could be explained
by an inadequate surveillance procedure before the CRC
diagnosis (ie, inadequate bowel preparation), inadequate
surveillance interval, or inadequate dysplasia manage-
ment. This suggests that the incidence of CRC could have
been even lower if surveillance was performed strictly
according to the guidelines in all patients. Several studies
have highlighted the problem of adherence to the CRC
surveillance guidelines in patients with long-standing
IBD.10–13 The relatively large number of potentially
preventable CRCs in the present surveillance cohort
stresses the importance of increasing the awareness of
both patients and gastroenterologists for adequately
performed surveillance at the appropriate interval.
The CRC incidence of 2.5 per 1000 person-years of
follow-up evaluation in the current study is substantially
lower than the incidence of 5.9 per 1000 person-years of
follow-up evaluation reported by Rutter et al,8 using a
large surveillance cohort, despite a similar study design.
This probably can be explained by the fact that our study
included data from the year 2000 onward, whereas the
Rutter et al8 cohort dates back to the 1970s. Large
population-based cohorts have shown that the incidence
Figure 1. All surveillance
colonoscopies and epi-
sodes of dysplasia before
the diagnosis of CRC. IFD,
indefinite for dysplasia.
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time, most likely reflecting the improvement in the
quality of endoscopes and colonoscopic performance
combined with improvements in anti-inflammatory
medication, which might well explain the lower inci-
dence of CRC in our study.14,15 In addition, the fact that
10% of surveillance procedures were performed with
chromoendoscopy could have improved the dysplasia
detection rate and thereby decreased the overall inci-
dence of CRC compared with previous studies.
Only 5 cases of interval CRC, defined as advanced-stage
CRC despite adequate surveillance at the appropriate in-
terval before the CRC diagnosis, were identified. Although
these CRCs constituted 30% of the total number of CRCs inFigure 2. CRC cases subdivided based on the most likely
etiologic factor.our cohort, the incidence of 0.7 per 1000 follow-up years
was considerably lower than the 2.7 per 1000 follow-up
years reported by Rutter et al.8 Again, the fact that our
data originate from a more recent era with improved en-
doscopes andmost likely a lower overall risk of CRC seems
a logical explanation for this discrepancy. Another more
recently published study on interval CRCs among IBD pa-
tients identified all cases of CRCdiagnosedduring orwithin
36 months after colonoscopy and compared the percent-
age of CRCs diagnosed 6 to 36 months after colonoscopy
(interval CRCs) out of the total number of CRCs between
patients with and without IBD.16 In this study, the per-
centage of interval CRCswas 3 times higher in IBD patients
compared with those without IBD, stressing the impor-
tance of close surveillance in these patients. This study
lacked data on the colonoscopies before the CRC diagnosis
including the number of biopsy specimens, bowel prepa-
ration, and the data to assess the appropriate surveillance
interval for each patient. Therefore, the number of interval
CRCs cannot be compared with our study.
Reports on the incidence of interval CRC (defined as
CRC after a negative colonoscopy) among patients
without IBD have ranged between 0.2 and 1.2 per 1000
years of follow-up evaluation.17,18 The incidence of true
interval CRCs in our study of 0.7 per 1000 years of
follow-up evaluation therefore is comparable with the
interval CRC incidence in patients undergoing surveil-
lance for sporadic CRC.
Two likely explanations for the occurrence of interval
CRCs are either missed dysplastic lesions or cancer
developing in the time between 2 surveillance colonos-
copies. Although it has been suggested that the carcino-
genesis in IBD-associated CRC might be accelerated as
compared with sporadic CRC, the fact that dysplasia in
IBD patients often is flat and therefore can be overlooked
more easily offers a plausible explanation for the
occurrence of interval CRCs in these patients.19,20 The
low rate of interval CRC in our cohort suggests that
missed lesions do not pose a large problem when sur-
veillance is performed at an interval of 1 to 2 years.
Although optimal surveillance intervals cannot be
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and interval CRC might justify surveillance intervals of 3
or even 5 years in patients without additional risk fac-
tors, as suggested in the updated BSG and European
Crohn’s and Colitis Organisation guidelines.3,21 Unfortu-
nately, we were unable to perform a risk-factor analysis
for interval CRCs because of the low number of such
cases identified in the current study.
Our study had several limitations that need to be
addressed. The low overall incidence of CRC in our sur-
veillance cohort precluded a meaningful analysis of risk
factors for interval CRCs.
The retrospective nature of this study resulted in
several limitations as well. First, the criteria for inade-
quate surveillance were based on endoscopy reports
rather than a standardized protocol, potentially intro-
ducing reporter bias regarding adequate bowel prepara-
tion and cecal intubation rate. Another potential
confounding factor might have been the classification of
lesions as either adenoma-like or non–adenoma-like
because this was based on the description of the lesion
taken from the endoscopy report.
Furthermore, we were unable to identify the reasons
why in some cases the recommended surveillance inter-
val was not used. This information is important because
this could guide an intervention toward either better
education of patients regarding the need for surveil-
lance or better understanding of the guidelines among
gastroenterologists.
In conclusion, this study showed that the incidence of
CRC is low among IBD patients undergoing regular
endoscopic surveillance. This might support the longer
surveillance interval of up to 5 years as recommended in
the current BSG and European Crohn’s and Colitis
Organisation guidelines, although the fact that one third
of all CRC cases appear to be interval carcinomas un-
derscores the need to further identify risk factors asso-
ciated with the development of interval cancer.References
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